ATE363275T1 - Pharmazeutische gelformulierung enthaltend eine trizyklische substanz (fk-506/tacrolimus) - Google Patents

Pharmazeutische gelformulierung enthaltend eine trizyklische substanz (fk-506/tacrolimus)

Info

Publication number
ATE363275T1
ATE363275T1 AT99917179T AT99917179T ATE363275T1 AT E363275 T1 ATE363275 T1 AT E363275T1 AT 99917179 T AT99917179 T AT 99917179T AT 99917179 T AT99917179 T AT 99917179T AT E363275 T1 ATE363275 T1 AT E363275T1
Authority
AT
Austria
Prior art keywords
tacrolimus
formulation containing
gel formulation
pharmaceutical gel
tricyclic
Prior art date
Application number
AT99917179T
Other languages
English (en)
Inventor
Rinta Ibuki
Fumio Shimojo
Satoshi Ueda
Toshihiko Toyoda
Masayuki Yamanaka
Erika Yoshida
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of ATE363275T1 publication Critical patent/ATE363275T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT99917179T 1998-04-27 1999-04-26 Pharmazeutische gelformulierung enthaltend eine trizyklische substanz (fk-506/tacrolimus) ATE363275T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11727198 1998-04-27

Publications (1)

Publication Number Publication Date
ATE363275T1 true ATE363275T1 (de) 2007-06-15

Family

ID=14707636

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99917179T ATE363275T1 (de) 1998-04-27 1999-04-26 Pharmazeutische gelformulierung enthaltend eine trizyklische substanz (fk-506/tacrolimus)

Country Status (24)

Country Link
US (2) US6673808B1 (de)
EP (1) EP1074255B1 (de)
JP (1) JP3732525B2 (de)
KR (1) KR100406823B1 (de)
CN (1) CN1161117C (de)
AR (1) AR018330A1 (de)
AT (1) ATE363275T1 (de)
AU (1) AU749475B2 (de)
BR (1) BR9910336A (de)
CA (1) CA2326222C (de)
DE (1) DE69936195T2 (de)
ES (1) ES2284248T3 (de)
HK (1) HK1038884B (de)
HU (1) HUP0104452A3 (de)
ID (1) ID29262A (de)
IL (1) IL139210A (de)
NO (1) NO20005399L (de)
NZ (1) NZ507345A (de)
PL (1) PL343627A1 (de)
RU (1) RU2203058C2 (de)
TR (1) TR200003108T2 (de)
TW (1) TW565461B (de)
WO (1) WO1999055332A1 (de)
ZA (1) ZA200005378B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
BR0011225A (pt) * 1999-04-30 2002-03-19 Sucampo Ag Agente para tratar de olhos secos, seu método e uso
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
ES2728739T3 (es) * 2001-02-19 2019-10-28 Novartis Pharma Ag Derivado de rapamicina para el tratamiento de un tumor sólido asociado con angiogénesis desregulada
GB0108498D0 (en) * 2001-04-04 2001-05-23 Novartis Ag Organic Compounds
AUPR529701A0 (en) * 2001-05-28 2001-06-21 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition
PE20030828A1 (es) * 2002-03-04 2003-11-04 Novartis Ag Composicion oftalmica que comprende ascomicina
GB0218996D0 (en) * 2002-08-14 2002-09-25 Novartis Ag Organic compounds
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US8092788B2 (en) 2004-03-03 2012-01-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
WO2006001251A1 (ja) * 2004-06-24 2006-01-05 Kowa Co., Ltd. アトルバスタチン外用剤組成物
EP1861112A4 (de) 2005-03-03 2009-07-22 Revance Therapeutics Inc Zusammensetzungen und verfahren zur topischen anwendung und transdermalen abgabe von botulinumtoxinen
WO2007011880A2 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
FR2900052B1 (fr) * 2006-04-19 2011-02-18 Galderma Sa Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
CN101288643B (zh) * 2008-06-17 2012-11-14 杨喜鸿 含有他克莫司的凝胶剂组合物及其制备方法和药物应用
ES2478845T3 (es) * 2008-10-08 2014-07-23 Takata Seiyaku Co., Ltd. Preparación de tacrolimus para aplicaciones externas
GB0917817D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
GB0917816D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
JP2011102260A (ja) * 2009-11-11 2011-05-26 Takada Seiyaku Kk タクロリムス外用剤
WO2012011192A1 (ja) * 2010-07-23 2012-01-26 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
JP5674786B2 (ja) * 2010-07-23 2015-02-25 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
EP2671583A4 (de) * 2011-01-31 2014-09-03 Univ Osaka Extern verwendetes arzneimittel zur behandlung von hautkrankheiten und herstellungsverfahren dafür
EP4094761A4 (de) * 2020-01-24 2023-12-27 Nobelpharma Co., Ltd. Rapamycin enthaltende externe zubereitung

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454113A (en) * 1982-09-21 1984-06-12 Scm Corporation Stabilization of oil and water emulsions using polyglycerol esters of fatty acids
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
ES2099112T3 (es) * 1990-09-04 1997-05-16 Fujisawa Pharmaceutical Co Pomadas que contienen un compuesto triciclico.
TW213418B (de) * 1991-05-02 1993-09-21 Kuko Seiyaku Kk
JPH06128148A (ja) * 1992-04-30 1994-05-10 Dotsuto:Kk 皮膚外用剤
JP2523428B2 (ja) * 1992-12-04 1996-08-07 エスエス製薬株式会社 消炎鎮痛ゲル製剤
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
GB2308546B (en) * 1994-10-26 1999-06-02 Novartis Ag Topical macrolide compositions
SI0812588T1 (en) * 1995-12-28 2005-02-28 Mitsubishi Pharma Corporation Pharmaceutical external preparations for topical administration comprising 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol for the treatment of diseases induced from immune disorder
CZ267796A3 (cs) * 1996-09-12 1998-04-15 Galena A.S. Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů
TW450810B (en) * 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
WO1998046268A1 (fr) * 1997-04-11 1998-10-22 Fujisawa Pharmaceutical Co., Ltd. Composition medicamenteuse

Also Published As

Publication number Publication date
HK1038884A1 (en) 2002-04-04
HUP0104452A2 (hu) 2002-03-28
TR200003108T2 (tr) 2001-02-21
ID29262A (id) 2001-08-16
IL139210A (en) 2005-11-20
US6586444B2 (en) 2003-07-01
JP3732525B2 (ja) 2006-01-05
WO1999055332A8 (fr) 2000-02-17
US6673808B1 (en) 2004-01-06
AR018330A1 (es) 2001-11-14
HK1038884B (zh) 2005-05-06
DE69936195D1 (de) 2007-07-12
CN1161117C (zh) 2004-08-11
US20020061907A1 (en) 2002-05-23
WO1999055332A1 (fr) 1999-11-04
HUP0104452A3 (en) 2004-05-28
DE69936195T2 (de) 2007-09-13
PL343627A1 (en) 2001-08-27
ZA200005378B (en) 2002-08-23
CA2326222A1 (en) 1999-11-04
AU749475B2 (en) 2002-06-27
BR9910336A (pt) 2001-09-25
NZ507345A (en) 2002-12-20
EP1074255B1 (de) 2007-05-30
AU3537299A (en) 1999-11-16
NO20005399D0 (no) 2000-10-26
RU2203058C2 (ru) 2003-04-27
TW565461B (en) 2003-12-11
NO20005399L (no) 2000-10-26
CN1307475A (zh) 2001-08-08
IL139210A0 (en) 2001-11-25
EP1074255A1 (de) 2001-02-07
CA2326222C (en) 2008-09-23
ES2284248T3 (es) 2007-11-01
KR100406823B1 (ko) 2003-11-21
KR20010042589A (ko) 2001-05-25
EP1074255A4 (de) 2002-02-13

Similar Documents

Publication Publication Date Title
DE69936195D1 (de) Pharmazeutische gelformulierung enthaltend eine trizyklische substanz (fk-506/tacrolimus)
DE69726015D1 (de) Pharmazeutische zusammensetzung enthaltend koenzym q-10
ATE234078T1 (de) Pharmazeutische omeprazol-formulierung
DE69525148D1 (de) Pharmazeutische formulierung
DE69814091D1 (de) Voriconazol-enthaltende pharmazeutische zubereitungen
ATE228823T1 (de) Pharmazeutische aerosolformulierung
DE69940904D1 (de) Pharmazeutische zusammensetzung enthaltend epothilone
ATE331529T1 (de) Antigen enthaltende pharmazeutische zusammensetzung
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
DE59712959D1 (de) Orale pharmazeutische zubereitung enthaltend ibandronat
HUP0004534A3 (en) Pharmaceutical formulation containing olanzapine
FI954767A (fi) Lipofiilisiä lääkeaineita sisältävä farmaseuttinen koostumus
DE69831620D1 (de) Arzneizubereitungen enthaltend Kannabinoide
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
ATE432707T1 (de) Pharmazeutische zubereitung
NO981008D0 (no) Farmasöytisk formulering
ATE383868T1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
DE10084344T1 (de) Cyclosporin enthaltende pharmazeutische Zusammensetzung
DE59801987D1 (de) Pharmazeutische zusammensetzung enthaltend peptichemio
DE69708130T2 (de) A-oxo-butansäuren enthaltende pharmazeutische zusammensetzung
ATE260094T1 (de) Mikronisierte bicyclische arzneistoffe enthaltende pharmazeutische zusammensetzungen
ID30032A (id) Formulasi farmasi
DE69907735D1 (de) Melatoninderivate und diese enthaltende pharmazeutische zubereitung
AR025867A1 (es) Formulacion portasdora farmaceutica
NO20004816D0 (no) Ny farmasøytisk formulering

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties